Ecolab has launched its Life Sciences cleanroom programme in North America. Developed specifically for pharmaceutical manufacturing, Ecolab’s cleanroom programme provides comprehensive cleaning and disinfection for both sterile and non-sterile applications, and includes the company’s Klercide chemistry line and SteriShield Delivery System.
Ecolab’s offering is designed to ensure the highest level of patient and worker safety, while improving compliance and operational efficiency.
“Ecolab Life Sciences is a market leader in Europe for cleanroom cleaning and disinfection solutions, and partners with many of the world’s top pharmaceutical manufacturing companies,” said Beth Simermeyer, Ecolab executive vice president for Life Sciences. “We are excited to expand our proven cleanroom solutions to help North American pharmaceutical manufacturers improve cleanroom operations.”
The Klercide product line of cleanroom alcohol, biocide and detergent chemistries complements Ecolab’s existing clean-in-place (CIP) and clean-out-of-place (COP) program, which is branded under the COSA name and already available in both North America and Europe.
Ecolab’s patented, ready-to-use SteriShield Delivery System, a closed and validated trigger spray system that ensures content integrity throughout use, is available across the Klercide product range. Other product formats for the cleanroom environment include concentrates and mop and pouch wipes.
Beyond chemistry, Ecolab Life Sciences also addresses pharmaceutical manufacturers’ specific needs with its Total Plant Solutions offering, which, in addition to cleaning and disinfection programs, also includes cleaning and disinfection validation support, technical lab support, regulatory and scientific insights, site surveys and customer training.
Ecolab is investing in a new manufacturing facility in Greensboro, North Carolina, US, to support the launch of the North American cleanroom portfolio.
“Our industry expertise, solutions and integrated business model helps ensure that we provide consistency across customers’ pharmaceutical operations in North America and other sites around the globe to drive improvements in safety, compliance, and operational efficiency,” Simermeyer concluded.
